A18.4 Tuberculosis of skin and subcutaneous tissue

Name of the Condition

• Tuberculosis of skin and subcutaneous tissue
• ICD Code: A18.4

Summary

Tuberculosis of skin and subcutaneous tissue is a form of extrapulmonary tuberculosis where Mycobacterium tuberculosis infects the skin or underlying subcutaneous tissues. This condition typically results from the spread of TB bacteria from a primary site, usually the lungs, via the bloodstream or lymphatic system. It can present as localized lesions or nodules and may involve the dermis, subcutaneous fat, or deeper tissues.

Causes

Tuberculosis of skin and subcutaneous tissue is caused by the dissemination of Mycobacterium tuberculosis from an existing infection, most commonly pulmonary tuberculosis. The bacteria may travel to the skin or subcutaneous tissues during active disease or reactivation of latent TB. Direct inoculation is rare but possible in certain cases.

Risk Factors

• Immunocompromised states, such as HIV/AIDS or chronic immunosuppressive therapy.
• History of untreated or inadequately treated tuberculosis.
• Close contact with individuals who have active TB.
• Living in or traveling to regions with high TB prevalence.
• Underlying conditions like diabetes or malnutrition.

Symptoms

• Skin lesions, such as papules, nodules, or ulcers.
• Subcutaneous nodules or abscesses.
• Pain or tenderness in affected areas.
• Discharge or drainage from lesions.
• Systemic symptoms of TB, such as fever, night sweats, or weight loss.

Diagnosis

Diagnosis involves clinical evaluation of skin or subcutaneous lesions, followed by laboratory testing. A biopsy of the affected tissue may be performed to identify Mycobacterium tuberculosis through histopathology, culture, or molecular testing. Imaging studies may be used to assess the extent of involvement. Sputum or other samples may be tested if pulmonary TB is suspected.

Treatment Options

Treatment typically involves a standard course of anti-tuberculosis medications, such as isoniazid, rifampin, pyrazinamide, and ethambutol, administered for several months. The regimen may be adjusted based on drug resistance or patient-specific factors. Local wound care may be necessary for skin lesions.

Prognosis and Follow-Up

With appropriate treatment, the prognosis is generally good, though recovery may take time. Follow-up is essential to monitor for treatment response, potential drug resistance, or recurrence. Regular clinical assessments and imaging may be used to evaluate healing.

Complications

• Delayed healing or chronic skin lesions.
• Scarring or disfigurement.
• Spread of infection to other areas.
• Drug resistance if treatment is incomplete or inadequate.

Lifestyle & Prevention

• Adhere to prescribed anti-TB medications to prevent recurrence.
• Practice good wound care for skin lesions.
• Avoid close contact with individuals who have active TB.
• Maintain overall health to support immune function.

When to Seek Professional Help

Seek medical attention if skin lesions worsen, new symptoms develop, or systemic signs of TB (e.g., fever, weight loss) occur. Prompt evaluation is important for effective management.

Tips for Medical Coders

When coding A18.4, ensure documentation specifies the involvement of skin or subcutaneous tissue. Differentiate from other extrapulmonary TB sites (e.g., bones, genitourinary) to avoid miscoding. Confirm the diagnosis aligns with clinical findings and laboratory results.